Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29751463 | 1.00 | IMPDH2 (0.43) | IMPDH2CLK1DYRK1ATNFHTR2A | |
| SCHEMBL15201623 | 0.84 | IMPDH2 (0.61) | IMPDH2DYRK1AHTR2AHTR2CHTR2B | |
| SCHEMBL31629068 | 0.84 | IMPDH2 (0.61) | IMPDH2DYRK1AHTR2AHTR2CHTR2B | |
| SCHEMBL8404561 | 0.81 | CYP2A6 (0.52) | CLK1DYRK1ATNFHTR2AHTR2C | |
| SCHEMBL29129334 | 0.78 | AXL (0.46) | IMPDH2CLK1DYRK1ATNFHTR2A | |
| SCHEMBL3240722 | 0.76 | POLB (0.53) | IMPDH2CLK1DYRK1ATNFAXL | |
| SCHEMBL15058583 | 0.76 | IMPDH2 (0.43) | IMPDH2CLK1DYRK1ATNFHTR2A | |
| SCHEMBL3714977 | 0.76 | IMPDH2 (0.72) | IMPDH2CLK1DYRK1ATNFHTR2A | |
| SCHEMBL30709993 | 0.76 | IMPDH2 (0.43) | IMPDH2CLK1DYRK1ATNFHTR2A | |
| SCHEMBL27040501 | 0.76 | IMPDH2 (0.43) | IMPDH2CLK1DYRK1ATNFHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| CN-113508118-B | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | ASTRAZENECA, AB (SE) | 2022-08-09 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| EP-3935060-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | Astrazeneca AB (SE) | 2022-01-12 | — | — | EP | disclosed |
| CN-111233859-B | Organic compound, organic electroluminescent material and application thereof | 武汉天马微电子有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3790884-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | Astrazeneca AB (SE) | 2021-03-17 | — | — | EP | disclosed |
| CN-112074520-A | Tetracycloheteroaryl compounds | 阿斯利康(瑞典)有限公司 | 2020-12-11 | — | — | CN | disclosed |
| CN-111233859-A | Organic compound, organic electroluminescent material and application thereof | 上海天马有机发光显示技术有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | IMPDH2 590/4885CLK1 3179/4885DYRK1A 3566/4885 |
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | IMPDH2 1112/4885CLK1 3000/4885DYRK1A 3049/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | IMPDH2 590/4885CLK1 3179/4885DYRK1A 3566/4885 |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | IMPDH2 1112/4885CLK1 3000/4885DYRK1A 3049/4885 |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | CCNI, MCL1, MKI67 | IMPDH2 2197/4885CLK1 2258/4885DYRK1A 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.